Status:
COMPLETED
Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation
Lead Sponsor:
University of Kansas Medical Center
Conditions:
Pregnancy; Nutritional Diseases
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and...
Eligibility Criteria
Inclusion
- Participants for this study are invited from the parent study, ADORE. Eligibility listed reflects criteria for the ADORE study.
- Agree to consume study capsules and a typical prenatal supplement of 200 mg DHA
- Available by telephone
Exclusion
- Expecting multiple infants
- Gestational age at baseline \<12 weeks or \>20 weeks
- Unable or unwilling to agree to consume capsules until delivery
- Unwilling to discontinue use of another prenatal supplement with DHA that contains ≥ 200 mg DHA
- Women with allergy to any component of DHA product (including algae), soybean oil or corn oil
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
254 Patients enrolled
Trial Details
Trial ID
NCT03310983
Start Date
November 1 2017
End Date
August 31 2022
Last Update
October 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Kansas Medical Center
Kansas City, Kansas, United States, 66160